TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31123057

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy at flows of 8-2 L/min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy
Number of subjects: 44
Study: 31343947

Group type: EXPERIMENTAL
Intervention: Essential amino acid supplementation (EAAs) - 20 g, twice daily for 7 days before TKA and for 6 weeks after surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 28086853

Group type: EXPERIMENTAL
Intervention: Telephone counselor delivered pedometer‐mediated walking intervention (6 sessions over 8-10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (informational brochure and a pedometer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone counselor delivered pedometer‐mediated walking intervention
Number of subjects: 0
Study: 26950740

Group type: EXPERIMENTAL
Intervention: Subcutaneous talc
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 23258530

Group type: EXPERIMENTAL
Intervention: Low-dose pegylated interferon (IFN)
Number of subjects: 1319
Study: 21323251

Group type: EXPERIMENTAL
Intervention: Anxious-mood induction (video of interviews with frontline nurses and doctors during the SARS epidemic)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calm-mood induction (video of a nursing student's pleasant orientation to a clinical placement site)
Number of subjects: 30
Study: 19338588

Group type: EXPERIMENTAL
Intervention: 2% benzophenone‐4
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 5% benzophenone‐4
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 5% methylene bis‐benzotriazolyl tetramethylbutylphenol
Number of subjects: 94
Study: 16703971

Group type: EXPERIMENTAL
Intervention: Intradiscal injection of hypertonic dextrose (50% dextrose and 0.25% Bupivacaine)
Number of subjects: 0
Study: 15155329

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg succinylcholine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg succinylcholine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg succinylcholine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 100
Study: 11205409

Group type: EXPERIMENTAL
Intervention: Skin Disease Prevention Program (SDPP) including individual skin care and protection regimes, skin care and protection products, and seminars.
Number of subjects: 29
Study: 9701409

Group type: EXPERIMENTAL
Intervention: Theophylline (median dose 250 mg twice daily; range 250-375 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8124700

Group type: EXPERIMENTAL
Intervention: 2.3% sodium fluoride varnish
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 1.1% sodium fluoride varnish
Number of subjects: 274

Group type: COMPARATOR
Intervention: Comparison of 2.3% and 1.1% varnish
Number of subjects: 274
Study: 2811065

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg (F)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Chlorothiazide 500 mg (C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Furosemide with spironolactone (100 mg b.i.d.) (F + S)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chlorothiazide during furosemide infusion
Number of subjects: 9
Study: 780312

Group type: EXPERIMENTAL
Intervention: Renografin 76
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isopaque 370
Number of subjects: 58
Study: 30664239

Group type: EXPERIMENTAL
Intervention: Deprescribing intervention (electronic alerts combined with pharmacist support to deprescribe anticholinergics and benzodiazepines)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 29166987

Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR) treatment, four 20-minute sessions at weekly intervals.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 19
Study: 25912475

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 250

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study: 23274511

Group type: EXPERIMENTAL
Intervention: 10,000 IU urinary hCG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 250 μg recombinant hCG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 500 μg recombinant hCG
Number of subjects: 180
Study: 22004426

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: No bariatric surgery (control group)
Number of subjects: 100
Study: 19596014

Group type: EXPERIMENTAL
Intervention: Infliximab (5 or 10 mg/kg) intravenously at weeks 0, 2, and 6, then every 8 weeks through week 46 (ACT‐1) or 22 (ACT‐2)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 728
Study: 16498861

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 100
Study: 14600929

Group type: EXPERIMENTAL
Intervention: Plasma clearance of (99m)Tc‐HEPIDA (Cl(Pl))
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Liver clearance of (99m)Tc‐HEPIDA (Cl(Hp))
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Correlation of individual values of both clearances with individual score of liver damage
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Factorial analysis for parenchyma performance
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Assessment of liver performance
Number of subjects: 131
Study: 10499754

Group type: EXPERIMENTAL
Intervention: 100 microg (1 mL) clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 mL preservative‐free normal saline mixed with local anesthetic (7 mL 1% preservative‐free lidocaine)
Number of subjects: 40
Study: 8815563

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (oral coumadin or standard intravenous heparin)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sinus rhythm patients (control group)
Number of subjects: 69
Study: 1903407

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 156
Study: 7226713

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg) administered via intravenous infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg) oral tablet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg)
Number of subjects: 6
Study: 28366302

Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft
Number of subjects: 160
Study: 26299540

Group type: EXPERIMENTAL
Intervention: Fixed, low radiant exposure diode laser treatments
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Incremental radiant exposure diode laser treatments
Number of subjects: 39
Study: 25336915

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Evogliptin 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Evogliptin 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22448936

Group type: EXPERIMENTAL
Intervention: Real TENS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 20
Study: 20214474

Group type: EXPERIMENTAL
Intervention: Acyclovir suppressive therapy (400 mg twice daily)
Number of subjects: 0
Study: 17878471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0
Study: 15597186

Group type: EXPERIMENTAL
Intervention: Estimation with equal numbers of elements on both scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher number of elements on the unattended scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower number of elements on the unattended scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response cues blocked in Experiment 2
Number of subjects: 0
Study: 12401594

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl/midazolam
Number of subjects: 40
Study: 10187877

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 31951862

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake (% of total energy intake)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fat intake (% of total energy intake)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Absolute intake of ω‐3
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Absolute intake of vitamin D
Number of subjects: 23
Study: 30890624

Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.1%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 28506865

Group type: EXPERIMENTAL
Intervention: Neurological prognostication recommendations (continue, not escalate, withdraw)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Prognosticated patients
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: WLST patients
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Recommendations for care (continue, not escalate, withdraw)
Number of subjects: 939
Study: 25609032

Group type: EXPERIMENTAL
Intervention: Vertise Flow™
Number of subjects: 46

Group type: COMPARATOR
Intervention: Universal Dentine Sealant
Number of subjects: 46

Group type: COMPARATOR
Intervention: Clearfil Protect Bond
Number of subjects: 46

Group type: COMPARATOR
Intervention: Flor-Opal® Varnish
Number of subjects: 46
Study: 23239219

Group type: EXPERIMENTAL
Intervention: Total atrial conduction time (PA‐TDI duration)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: LA maximum volume
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prolonged PA‐TDI duration
Number of subjects: 128
Study: 21658750

Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 U aXa o.d.
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 IU t.i.d.
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Combined endpoint of proximal DVT, symptomatic non-fatal PE and VTE related death
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 1239
Study: 18697887

Group type: EXPERIMENTAL
Intervention: risk information leaflet
Number of subjects: 3185

Group type: EXPERIMENTAL
Intervention: risk and screening information leaflet
Number of subjects: 3185

Group type: COMPARATOR
Intervention: control‐‐no information
Number of subjects: 3185
Study: 21746765

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 465

Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Combination of aliskiren and losartan
Number of subjects: 465
Study: 16145378

Group type: COMPARATOR
Intervention: Standard dose of intravesical BCG (81 mg)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Decreased dose of intravesical BCG (27 mg)
Number of subjects: 155
Study: 11793426

Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg) with levodopa/carbidopa (100/125 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with levodopa/carbidopa (100/125 mg)
Number of subjects: 12
Study: 9519342

Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoproteins (VLDL, IDL, apolipoprotein B-containing lipoprotein particles, apolipoprotein C-III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoproteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesteryl-ester rich lipoproteins (LDL cholesterol)
Number of subjects: 0
Study: 7977607

Group type: EXPERIMENTAL
Intervention: 100,000-IU dose of vitamin A
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 200,000-IU dose of vitamin A
Number of subjects: 114
Study: 3184215

Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin (Clind/Gent)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mezlocillin (Mezlo)
Number of subjects: 147
Study: 11514818

Group type: EXPERIMENTAL
Intervention: Side posture manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction (mostly flexion distraction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 0
Study: 30617480

Group type: EXPERIMENTAL
Intervention: Retrospective measurements based on modified RECIST criteria
Number of subjects: 41

Group type: COMPARATOR
Intervention: Primary measurements by clinical radiologists
Number of subjects: 41

Group type: COMPARATOR
Intervention: Primary measurements
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Primary and retrospective measurements
Number of subjects: 41
Study: 30535865

Group type: EXPERIMENTAL
Intervention: Mobile CT examination workflow (study group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional stationary workflow (reference group)
Number of subjects: 98
Study: 26584960

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 158

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 158
Study: 25007692

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GVL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Flexible fiberoptic bronchoscope (FOB)
Number of subjects: 64
Study: 22343419

Group type: EXPERIMENTAL
Intervention: Realsil (RA)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 179
Study: 21431257

Group type: EXPERIMENTAL
Intervention: Submerged healing (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-submerged healing (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 17885543

Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine retard vs ACE inhibitors
Number of subjects: 0
Study: 15166882

Group type: EXPERIMENTAL
Intervention: High-dose radioiodine (100 mCi iodine-131)
Number of subjects: 142
Study: 12237621

Group type: EXPERIMENTAL
Intervention: Levormeloxifene 0.5 mg daily
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: Levormeloxifene 1.25 mg daily
Number of subjects: 2924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2924
Study: 9665228

Group type: EXPERIMENTAL
Intervention: HERS cohort
Number of subjects: 2763
Study: 7865643

Group type: EXPERIMENTAL
Intervention: Bran supplementation (12 g/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bran supplementation
Number of subjects: 80
Study: 2717904

Group type: EXPERIMENTAL
Intervention: 0.01% (w/v) PGE1 solution in saline injected under the mucoperiosteum palatal to the test tooth
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline injected palatal to the contralateral control tooth
Number of subjects: 5
Study: 31654125

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific exercises)
Number of subjects: 48
Study: 30455261

Group type: EXPERIMENTAL
Intervention: Elamipretide
Number of subjects: 0
Study: 28974265

Group type: EXPERIMENTAL
Intervention: Attentional bias training
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Approach bias training
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo version of attentional bias training
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo version of approach bias training
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: All interventions (attentional and approach bias training, placebo versions)
Number of subjects: 182
Study: 26569470

Group type: COMPARATOR
Intervention: Standard packaging alone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard packaging + pre-existing warning label
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard packaging + large customized warning label
Number of subjects: 118
Study: 24660584

Group type: EXPERIMENTAL
Intervention: Modified Sishen Wan (treatment group A)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo, Chao Maiya (control group B)
Number of subjects: 240
Study: 21601513

Group type: EXPERIMENTAL
Intervention: Actual pain
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutral stimulus
Number of subjects: 15

Group type: COMPARATOR
Intervention: Actual heat
Number of subjects: 15

Group type: COMPARATOR
Intervention: Expected heat
Number of subjects: 15

Group type: COMPARATOR
Intervention: Expected pain
Number of subjects: 15
Study: 18349203

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 200
Study: 16473497

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hypocaloric glucose
Number of subjects: 13
Study: 12648685

Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day
Number of subjects: 261

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 261
Study: 10365011

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.25 micrograms kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 8654642

Group type: EXPERIMENTAL
Intervention: 4 IU human GH
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 12 IU human GH
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2068563

Group type: EXPERIMENTAL
Intervention: Defibrotide 400 mg three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6185109

Group type: EXPERIMENTAL
Intervention: Short‐course, high fractional dose radiation therapy (6,000 to 7,000 rad in six to seven weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional protracted radiation schedule (4,000 to 4,800 rad in two to three weeks)
Number of subjects: 64
Study: 30409049

Group type: EXPERIMENTAL
Intervention: Client-centred ADL intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual ADL interventions
Number of subjects: 280
Study: 30570087

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture at energy balance points and points indicated for pain treatment.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo group with fixed placebo points.
Number of subjects: 31
Study: 26817503

Group type: EXPERIMENTAL
Intervention: Zinc and multivitamin (Zn+MV) supplementation
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Zinc-only supplementation
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study: 24642984

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 µg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vaginal estradiol (50 µg for 7 days)
Number of subjects: 48
Study: 21972268

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 28
Study: 19171852

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 3405

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 3405

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 3405

Group type: COMPARATOR
Intervention: Bivalirudin with or without IIb/IIIa inhibitors
Number of subjects: 3405
Study: 17254485

Group type: EXPERIMENTAL
Intervention: Embolization for gastric fundus varices combined with endoscopic variceal ligation (EVL) for esophageal varices
Number of subjects: 172

Group type: COMPARATOR
Intervention: Embolization for gastric fundus varices
Number of subjects: 172
Study: 16342093

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly subcutaneously
Number of subjects: 26
Study: 12505222

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10598302

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with milnacipran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Episodic treatment
Number of subjects: 0
Study: 7721386

Group type: EXPERIMENTAL
Intervention: Perindopril (4 to 8 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg/d)
Number of subjects: 25
Study: 1974271

Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) 200 mg, administered b.i.d.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immediate Release (IR) 200 mg, administered b.i.d.
Number of subjects: 13
Study: 6119509

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unchanged conventional treatment (UCT)
Number of subjects: 32
Study: 31887537

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658
Study: 28742225

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 27670138

Group type: EXPERIMENTAL
Intervention: Computerised approach bias modification (10 sessions)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham training (control condition)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Computerised approach bias modification
Number of subjects: 54
Study: 24290406

Group type: EXPERIMENTAL
Intervention: Shorter modified acetylcysteine regimen (12 h)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard acetylcysteine regimen (20.25 h)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Ondansetron pretreatment (4 mg)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (no antiemetic pretreatment)
Number of subjects: 222
Study: 22935043

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20541000

Group type: EXPERIMENTAL
Intervention: Cutanova Nanorepair Q10 cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: NLC negative control cream
Number of subjects: 0